Developmental Research Program

发展研究计划

• 批准号: 10333520
• 负责人: Jason S. Lewis
• 金额: $ 12.35万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333520
• 关键词: Award; Clinical Trials; Collaborations; Combined Modality Therapy; Data; Development; Doctor of Philosophy; Extramural Activities; Faculty; Funding; Genomics; Goals; Immunotherapeutic agent; Individual; Institution; Investigation; Islet Cell Tumor; Leadership; Malignant neoplasm of pancreas; Memorial Sloan-Kettering Cancer Center; Outcome; Pancreas; Participant; Patient Care; Peer Review; Pilot Projects; Program Research Project Grants; Publications; Recording of previous events; Request for Proposals; Research; Research Personnel; Research Support; Resources; Seeds; Translational Research; Underrepresented Populations; United States National Institutes of Health; Universities; Vision; Women' s Group; anticancer research; base; biomarker development; clinical care; equity diversity and inclusion; innovation; medical schools; novel strategies; pancreatic neoplasm; preference; programs; radiomics; stem; success; translational cancer research; translational goal

PROJECT SUMMARY/ABSTRACT – DRP The goals of the Developmental Research Program (DRP) of the MSK Pancreas SPORE are to expand the breadth of the translational pancreatic cancer research base and to encourage highly innovative investigations that have major potential to impact pancreatic cancer outcomes. DRP funds, supplemented by institutional funds, will allow us to support 2 exceptional pilot projects each year. We will request proposals for pilot projects with a clear translational focus and with potential to ultimately impact clinical care of patients with pancreatic neoplasms. Investigators (MD, MD/PhD, DO, or PhD) with a demonstrated history of pancreas cancer research appointed at MSK or a neighboring institution, Weill Cornell Medical College and the Rockefeller University, will be eligible to apply. Applications will be peer-reviewed by the CEP/DRP Selection Committee, which is composed of the SPORE PIs, DRP and CEP Leaders, select MSK Departmental and Divisional Chairs, and representatives from the MSK Equality, Diversity & Inclusion Council. The most meritorious projects based on defined review criteria will be selected. Preference will be given to projects that advance the long-term research goals of the SPORE and have high potential to become full SPORE projects. We will prioritize projects submitted by early-stage investigators and are committed to promoting diversity and strengthening the participation of women and underrepresented groups in translational research. DRP awardees will have full access to SPORE Core resources, will benefit from the expertise of the SPORE investigative team, and will be active participants in the SPORE. The scientific progress of DRP projects will be evaluated every six months by the DRP Leaders. Long-term metrics of success for DRP awardees include presentation/publication of original research, successful competition for independent research support, successful development and completion of clinical trials stemming from DRP research, establishment of new collaborations, and institutional recognition by academic promotion. DRP projects that make significant progress towards their translational goals will be eligible for a second year of funding and have the potential to be promoted to full SPORE projects.

项目摘要/摘要 - DRP MSK胰腺孢子的发展研究计划（DRP）的目标是扩展 翻译的胰腺癌研究基础的广度，并鼓励高度创新的研究 具有影响胰腺癌预后的主要潜力。由机构资金补充的DRP资金， 每年将允许我们支持两个杰出的试点项目。我们将要求提供有关试点项目的建议 清晰的翻译重点，并有可能影响胰腺患者的临床护理 肿瘤。研究人员（MD，MD/PHD，DO或PHD），具有胰腺癌研究史 威尔·康奈尔医学院（Weill Cornell Medical College）和洛克菲勒大学（Will）任命为MSK或邻近机构，将 有资格申请。申请将由CEP/DRP选拔委员会进行同行评审，这是 由孢子PI，DRP和CEP领导者，精选的MSK部门和部门椅子组成，以及 MSK平等，多样性与包容委员会的代表。基于 将选择定义的审核标准。优先考虑推进长期研究的项目 孢子的目标，具有成为全孢子项目的高潜力。我们将优先考虑提交的项目 由早期调查人员进行，并致力于促进多样性并加强参与 妇女和人为群体不足的群体。 DRP获奖者将有完整的孢子访问权限 核心资源将受益于孢子调查团队的专业知识，并将成为活跃的参与者 在孢子中。 DRP领导者将每六个月评估DRP项目的科学进步。 DRP获奖者成功的长期指标包括介绍/出版原始研究，成功 竞争独立研究支持，成功开发和完成临床试验的竞争 来自DRP研究，建立新的合作以及学术的机构认可 晋升。 DRP项目朝着翻译目标取得重大进展的项目将有资格 资金的第二年，有可能晋升为完整的孢子项目。